S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
NASDAQ:CYTO

Altamira Therapeutics Stock Competitors

$1.50
0.00 (0.00%)
(As of 12/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.48
$1.60
50-Day Range
$1.50
$2.40
52-Week Range
$1.33
$6.25
Volume
136,321 shs
Average Volume
2.90 million shs
Market Capitalization
$17.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.9

Altamira Therapeutics (NASDAQ:CYTO) Vs. ASRT, GLTO, ODT, EVFM, ZSAN, AGRX, OCUP, ABEO, ELDN, and JAGX

Should you be buying Altamira Therapeutics stock or one of its competitors? The main competitors of Altamira Therapeutics include Assertio (ASRT), Galecto (GLTO), Odonate Therapeutics (ODT), Evofem Biosciences (EVFM), Zosano Pharma (ZSAN), Agile Therapeutics (AGRX), Ocuphire Pharma (OCUP), Abeona Therapeutics (ABEO), Eledon Pharmaceuticals (ELDN), and Jaguar Health (JAGX). These companies are all part of the "pharmaceutical preparations" industry.

Altamira Therapeutics vs.

Galecto (NASDAQ:GLTO) and Altamira Therapeutics (NASDAQ:CYTO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GalectoN/AN/A-$34.84 millionN/AN/A
Altamira TherapeuticsN/AN/A-$8.75 millionN/AN/A

Galecto has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Altamira Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.

45.1% of Galecto shares are owned by institutional investors. Comparatively, 11.5% of Altamira Therapeutics shares are owned by institutional investors. 8.1% of Galecto shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Galecto had 3 more articles in the media than Altamira Therapeutics. MarketBeat recorded 6 mentions for Galecto and 3 mentions for Altamira Therapeutics. Galecto's average media sentiment score of 0.78 beat Altamira Therapeutics' score of -0.19 indicating that Galecto is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Galecto
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Altamira Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Altamira Therapeutics' return on equity of 0.00% beat Galecto's return on equity.

Company Net Margins Return on Equity Return on Assets
Galecto N/A -33.90% -32.58%
Altamira Therapeutics N/A N/A N/A

Galecto presently has a consensus price target of $11.50, suggesting a potential upside of 330.71%. Given Galecto's higher probable upside, analysts clearly believe Galecto is more favorable than Altamira Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galecto
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Altamira Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Galecto received 21 more outperform votes than Altamira Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
GalectoOutperform Votes
21
65.63%
Underperform Votes
11
34.38%
Altamira TherapeuticsN/AN/A

Summary

Galecto beats Altamira Therapeutics on 7 of the 11 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Altamira Therapeutics (NASDAQ:CYTO) vs. Its Competitors

TypeAltamira TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$17.13M$5.81B$4.96B$7.91B
Dividend YieldN/A2.63%2.05%2.56%
P/E RatioN/A16.2722.3123.43
Price / SalesN/A554.222,429.35276.02
Price / CashN/A146.2661.88204.50
Price / Book0.965.666.156.53
Net Income-$8.75M$95.55M$96.04M$154.44M
7 Day Performance-7.98%1.10%0.98%2.05%
1 Month Performance-6.25%-14.00%-12.06%-9.37%
1 Year PerformanceN/A5.47%9.29%26.38%

Altamira Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ASRT
Assertio
1.1031 of 5 stars
$1.52
flat
N/A+261.0%$67.84M$106.28M-1.6527
GLTO
Galecto
2.2048 of 5 stars
$2.67
flat
$11.50
flat
-81.7%$67.45MN/A0.0028
ODT
Odonate Therapeutics
2.3331 of 5 stars
$1.74
flat
$4.00
flat
-89.4%$66.97MN/A-0.64145
EVFM
Evofem Biosciences
1.6581 of 5 stars
$0.41
flat
$1.50
flat
-81.4%$66.89M$450K-0.23147
ZSAN
Zosano Pharma
1.9781 of 5 stars
$0.56
flat
$2.25
flat
-6.8%$66.04M$220K-1.9245
AGRX
Agile Therapeutics
2.1583 of 5 stars
$0.71
flat
$3.38
flat
-76.5%$65.66M$750K-0.9128High Trading Volume
OCUP
Ocuphire Pharma
2.0798 of 5 stars
$3.77
flat
$22.60
flat
-43.7%$65.22MN/A0.005Gap Down
ABEO
Abeona Therapeutics
2.2364 of 5 stars
$0.63
flat
$2.50
flat
-57.7%$64.62M$10M-1.11N/A
ELDN
Eledon Pharmaceuticals
2.1365 of 5 stars
$4.51
flat
$27.67
flat
N/A$64.53MN/A0.0010High Trading Volume
JAGX
Jaguar Health
1.8667 of 5 stars
$1.32
flat
$5.00
flat
+8.5%$63.64M$9.39M0.0034Negative News
BPTS
Biophytis
1 of 5 stars
$5.08
flat
N/AN/A$61.35MN/A0.002,020Gap Down
VYNE
VYNE Therapeutics
2.0115 of 5 stars
$1.14
flat
$6.50
flat
-83.1%$61.01M$20.99M-0.64106Analyst Report
Options Volume
Gap Down
High Trading Volume
GLMD
Galmed Pharmaceuticals
1.7 of 5 stars
$2.42
flat
$21.00
flat
-31.3%$60.70M$2.04M-1.6121Gap Up
ONTX
Onconova Therapeutics
1.9664 of 5 stars
$2.90
flat
$11.50
flat
-38.5%$60.27M$230K-2.3412Gap Up
SPRB
Spruce Biosciences
2.0414 of 5 stars
$2.55
flat
$10.33
flat
-89.5%$59.83MN/A-1.4217Analyst Upgrade
High Trading Volume
SNPX
Synaptogenix
0 of 5 stars
$8.86
flat
N/AN/A$59.13MN/A0.004
TPST
Tempest Therapeutics
1.6381 of 5 stars
$8.53
flat
$34.67
flat
-69.4%$58.94MN/A0.0013
MBRX
Moleculin Biotech
1.0581 of 5 stars
$2.06
flat
N/A-58.1%$58.87MN/A0.0013
APM
Aptorum Group
0.9064 of 5 stars
$1.65
flat
N/A-36.8%$58.75M$910K0.0025Gap Down
ARAV
Aravive
2.1064 of 5 stars
$2.79
flat
$23.33
flat
-51.6%$58.52M$5.68M-1.7817Gap Up
CALA
Calithera Biosciences
2.4498 of 5 stars
$0.78
flat
$3.67
flat
-83.1%$58.29M$22.25M-0.8393
LUMO
Lumos Pharma
2.1583 of 5 stars
$6.96
flat
$28.00
flat
-57.7%$58.17M$170K-2.1229
CLSN
Celsion
1.7248 of 5 stars
$0.67
flat
N/A+7.6%$57.82M$500K-2.5727
ADIL
Adial Pharmaceuticals
2.2915 of 5 stars
$2.77
flat
$11.00
flat
+38.5%$57.53MN/A-2.742,018
AYTU
Aytu Biopharma
1.7314 of 5 stars
$2.03
flat
$12.75
flat
+126.9%$57.14M$65.63M-0.5075Gap Up
High Trading Volume
ASLN
ASLAN Pharmaceuticals
1.9781 of 5 stars
$1.50
flat
$8.00
flat
-16.7%$56.99M$3M-3.132,020Analyst Report
News Coverage
Gap Up
MACK
Merrimack Pharmaceuticals
1.4598 of 5 stars
$4.19
flat
N/A-42.8%$56.19MN/A-18.2227
CEMI
Chembio Diagnostics
1.4798 of 5 stars
$1.82
flat
$8.00
flat
-71.4%$54.68M$32.47M-1.44355Gap Up
AEZS
Aeterna Zentaris
1.1114 of 5 stars
$0.45
flat
N/A+19.5%$54.57M$3.65M-6.4211
ONCS
OncoSec Medical
1.7915 of 5 stars
$1.39
flat
$11.00
flat
-74.6%$54.49MN/A-1.0244Upcoming Earnings
Gap Up
ALRN
Aileron Therapeutics
1.6064 of 5 stars
$0.59
flat
$3.50
flat
-41.7%$53.88MN/A-1.808
ADXN
Addex Therapeutics
1.6515 of 5 stars
$6.41
flat
$28.00
flat
-42.2%$52.64M$4.14M-2.5127
ADXS
Advaxis
1.6781 of 5 stars
$0.35
flat
$2.25
flat
+10.6%$51.61M$250K-1.8718Gap Up
RVPH
Reviva Pharmaceuticals
2.0333 of 5 stars
$3.68
flat
$10.00
flat
N/A$51.45MN/A-3.125
BFRI
Biofrontera
1.825 of 5 stars
$4.37
flat
$20.00
flat
N/A$50.69MN/A0.002,021Quiet Period Expiration
Gap Down
RNXT
RenovoRx
1.825 of 5 stars
$5.69
flat
$15.50
flat
N/A$50.69MN/A0.002,021
MITO
Stealth BioTherapeutics
1.5531 of 5 stars
$0.84
flat
$3.00
flat
-43.8%$48.20M$21.09M-2.042,020Gap Down
MNPR
Monopar Therapeutics
2.0198 of 5 stars
$3.82
flat
$29.00
flat
-20.5%$48.04MN/A-5.3010Gap Up
VRPX
Virpax Pharmaceuticals
0.3333 of 5 stars
$4.05
flat
N/AN/A$47.45MN/A0.002
GRAY
Graybug Vision
2.2498 of 5 stars
$2.22
flat
$5.75
flat
-90.5%$47.33MN/A0.0031
VCNX
Vaccinex
1.1331 of 5 stars
$1.52
flat
N/A-26.2%$46.82M$630K0.0040
INDP
Indaptus Therapeutics
2.2 of 5 stars
$5.70
flat
$16.00
flat
N/A$46.71MN/A-0.4440
ACXP
Acurx Pharmaceuticals
2.0333 of 5 stars
$4.53
flat
$12.00
flat
N/A$45.84MN/A0.003
FWP
Forward Pharma A/S
1.0848 of 5 stars
$6.29
flat
N/A-11.8%$44.16MN/A0.002,020Gap Down
APVO
Aptevo Therapeutics
2.3448 of 5 stars
$8.87
flat
$36.00
flat
-79.8%$43.45M$4.31M0.0058
CWBR
CohBar
2.4917 of 5 stars
$0.50
flat
$3.75
flat
-57.5%$42.77MN/A-1.7812
CLRB
Cellectar Biosciences
1.6331 of 5 stars
$0.70
flat
$4.25
flat
-70.4%$42.47MN/A-1.7011
HUGE
FSD Pharma
0.125 of 5 stars
$1.15
flat
N/A-35.0%$41.21M$190K-1.039
NERV
Minerva Neurosciences
2.2498 of 5 stars
$0.94
flat
$6.50
flat
-64.6%$40.07M$41.18M-1.1011Gap Up
DFFN
Diffusion Pharmaceuticals
1.0048 of 5 stars
$0.39
flat
N/A-49.7%$39.65MN/A-1.3910
This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.